The CenterWatch Monthly, June 2011
Sites rate Novo Nordisk, Roche, Amgen on top
A new CenterWatch survey of global investigative sites shows sponsors overall have improved their relationships with investigative sites during the past three years, as pharmaceutical companies increasingly focus on strategies to improve site quality and performance. Yet the average sponsor continues to fall below the performance expectations of investigative sites in several critical areas, including project management and study initiation activities. Six companies came out on top: Novo Nordisk, Roche, Amgen, Bayer, Abbott Laboratories and AstraZeneca. Three additional companies...
India and China: the reality behind the hype
Are India and China—two emerging markets that have been widely heralded as the hottest growth areas for clinical trials—really living up to all of the hype? A few years ago, analysts were predicting a massive shift in clinical trials from the developed world into emerging markets—India, specifically. In 2009, KPMG estimated the country of 1.2 billion people had the potential to be the foremost destination for R&D outsourcing. But instead of a rush of trials heading to the two countries, it has been more of a trickle. According to ClinicalTrials.gov, as of late April 2011 there were just...
Eye On Bayer HealthCare
Bayer HealthCare Pharmaceuticals (Bayer HCP) is the U.S.-based pharmaceutical company of Bayer HealthCare, which in turn is a subsidiary of Bayer. The Bayer group has a long history of more than a century developing, producing and marketing pharmaceuticals. Bayer HCP, in conjunction with leading pharmaceutical company Berlex, is ranked among the top 10 specialty pharmaceutical companies worldwide, which the companies attribute to their priorities on...
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.